Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.93
+0.03001.58%
Post-market: 1.940.0100+0.52%19:10 EST
Volume:2.31M
Turnover:4.40M
Market Cap:404.67M
PE:-1.25
High:1.95
Open:1.91
Low:1.85
Close:1.90
Loading ...

Press Release: Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

Dow Jones
·
29 Jan

Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
29 Jan

Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate

MT Newswires Live
·
28 Jan

Allogene announces FDA cleared IND application for study of ALLO-329

TIPRANKS
·
28 Jan

Allogene Therapeutics Inc - Resolution Trial to Begin Mid-2025

THOMSON REUTERS
·
28 Jan

Allogene Therapeutics Secures U.S. FDA Ind Clearance for Allo-329, Advancing Its Next-Generation Allogeneic Car T Into Autoimmune Diseases

THOMSON REUTERS
·
28 Jan

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

GlobeNewswire
·
28 Jan

Press Release: Vor Bio Announces $55.6 Million Private Placement

Dow Jones
·
27 Dec 2024

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Zacks
·
27 Dec 2024

Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
27 Dec 2024

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

Zacks
·
24 Dec 2024

PCRX Receives New Patent for Lead Pain Drug Exparel in the US

Zacks
·
05 Dec 2024

ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD

Zacks
·
05 Dec 2024

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?

Zacks
·
03 Dec 2024

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Zacks
·
28 Nov 2024

APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA

Zacks
·
28 Nov 2024